{"success":true,"data":{"pressRelease":{"id":"67843","rtpr_id":"nPn8Flbwla","ticker":"GRAL","exchange":"NASDAQ","all_tickers":["GRAL"],"title":"GRAL Shareholder Alert: Grail, Inc. Securities Class Action Lawsuit - Investors Should Contact SueWallSt","author":"PR Newswire","published_at":"2026-06-18T14:07:00.442Z","article_body":"GRAL Shareholder Alert: Grail, Inc. Securities Class Action Lawsuit - Investors Should Contact SueWallSt\n\nPR Newswire\n\nNEW YORK, June 18, 2026\n\nGrail Projected That the NHS-Galleri Trial Was Powered to Deliver a\nStatistically Significant Reduction in Late-Stage Cancers; Instead, the\nPrimary Endpoint Was Not Observed, and Investors Lost $51.32 Per Share\n\nNEW YORK, June 18, 2026 /PRNewswire/ -- Grail, Inc. (NASDAQ: GRAL) told\ninvestors its over 140,000-participant NHS-Galleri trial was designed to\nachieve a statistically significant reduction in Stage III and IV cancers. On\nFebruary 19, 2026, the company disclosed the opposite: the primary endpoint\n\"was not observed.\" GRAL shares collapsed 50.55% in a single day. Find out if\nyou can recover your investment losses\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4714095-11&h=2228923913&u=https%3A%2F%2Fsuewallst.com%2Flawsuits%2Fgrail-inc-class-action-lawsuit-gral%3Fprid%3D187605%26wire%3D4&a=Find+out+if+you+can+recover+your+investment+losses)\n or contact Joseph E. Levi, Esq. at jlevi@SueWallSt.com\n(mailto:jlevi@SueWallSt.com)  or (888) SueWallSt.\n\nFrom a closing price of $101.53 on February 19, 2026, shares fell to $50.21 on\nFebruary 20, 2026, a loss of $51.32 per share. The lead plaintiff deadline is\nAugust 4, 2026.\n\nThe Promise\n\nThroughout the Class Period of May 13, 2025 through February 19, 2026, Grail's\nleadership made specific, quantifiable representations about the NHS-Galleri\ntrial's trajectory:\n\n * On May 13, 2025, the company announced \"Positive Top-Line Results\" from the\nprevalent screening round, reporting a PPV \"substantially higher\" than the\n43% observed in PATHFINDER\n * Management stated the test was \"working in the real world,\" detecting\n\"clinically meaningful cancers and early-stage cancers in asymptomatic\nadults\"\n * On August 12, 2025, Grail's Chief Scientific Officer confirmed the study's\nsize \"was set to be able to deliver a statistically significant result\" on the\nprimary endpoint of late-stage cancer reduction\n * During the August 12, 2025 earnings call, executives promoted the NHS-Galleri\nreadout as a \"great calling card\" for global expansion and described the\nupcoming clinical utility data as a key catalyst\n * On October 20, 2025, management stated that PATHFINDER 2 results gave them \"a\nlot of confidence in the performance\" heading into the NHS-Galleri readout\nThe Reality\n\nOn February 19, 2026, Grail disclosed that the \"primary endpoint of\nstatistically significant Stage III-IV reduction was not observed.\" The\ncompany attributed this failure, in part, to \"probably need[ing] a longer\nfollow-up time to be able to [compare the study arms] adequately.\"\n\nThe lawsuit contends this admission reveals the three-year trial design and\nscreening duration were insufficient to demonstrate whether the primary\nendpoint was achievable, a limitation that should have been disclosed to\ninvestors rather than concealed behind repeated assurances of confidence.\n\nThe Numbers: Promised vs. Actual\n What Was Communicated                                                      What Actually Happened\n PPV \"substantially higher\" than 43%                                        Detailed results withheld from investors throughout Class Period\n Trial \"powered\" to deliver statistically significant late-stage reduction  Primary endpoint of Stage III-IV reduction not observed\n Three-year design sufficient for clinical utility                          Company admitted longer follow-up time was \"probably\" needed\n NHS-Galleri as a \"calling card\" for global expansion                       NHS and global partners left without the anticipated positive data\n PATHFINDER 2 gave \"a lot of confidence\" in performance                     Confidence did not translate to the primary endpoint\n\nWhat the Lawsuit Alleges About the Gap\n\nThe action claims that Grail's executives possessed information from their\ninternal review of first-round screening results that should have tempered\ntheir public confidence. By withholding detailed data under the stated\nrationale of protecting \"integrity\" of the trial, the complaint asserts\ndefendants potentially concealed known trendlines suggesting either a longer\ntimeline was necessary or that the probability of achieving the statistical\nreduction had diminished.\n\n\"Companies that make specific promises to investors about future performance\nhave an obligation to disclose known risks to those projections. When the gap\nbetween promise and reality is this significant, shareholders deserve to\nunderstand what was known and when.\" -- Joseph E. Levi, Esq.\n\nCheck whether you qualify to recover losses in the GRAL securities action\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4714095-11&h=1429650070&u=https%3A%2F%2Fsuewallst.com%2Flawsuits%2Fgrail-inc-class-action-lawsuit-gral%3Fprid%3D187605%26wire%3D4&a=Check+whether+you+qualify+to+recover+losses+in+the+GRAL+securities+action)\n or call (888) SueWallSt.\n\nABOUT SUEWALLST -- SueWallSt is a nationally recognized shareholder rights\nfirm. Over the past 20 years, the firm has secured hundreds of millions of\ndollars for aggrieved shareholders. Ranked in ISS Top 50 for seven consecutive\nyears.\n\nFrequently Asked Questions About the GRAL Lawsuit\n\nQ: What specific misstatements does the GRAL lawsuit allege? A: The complaint\nalleges Grail made materially false or misleading statements regarding the\nlikelihood of the NHS-Galleri trial achieving its primary endpoint of a\nstatistically significant reduction in Stage III and IV cancers. When the\ntrial's failure was disclosed on February 19, 2026, the stock price declined\nsharply.\n\nQ: How much did GRAL stock drop? A: Shares fell approximately 50.55%, a\ndecline of $51.32 per share, after the company disclosed that the primary\nendpoint of statistically significant Stage III-IV reduction was not observed.\nInvestors who purchased shares during the Class Period at artificially\ninflated prices may be entitled to compensation.\n\nQ: What do GRAL investors need to do right now? A: Gather brokerage records\nincluding purchase dates, share quantities, and prices paid. Contact SueWallSt\nfor a free, no-obligation evaluation at jlevi@SueWallSt.com\n(mailto:jlevi@SueWallSt.com)  or (888) SueWallSt. No immediate action is\nrequired to remain eligible as a class member.\n\nQ: What if I already sold my GRAL shares -- can I still recover losses? A:\nYes. Eligibility is based on when you purchased, not whether you still hold\nthem. Investors who bought during the Class Period and sold at a loss may\nstill participate.\n\nQ: Do I need to go to court or give testimony? A: No. The overwhelming\nmajority of class members never appear in court or give depositions. You\nsubmit a claim form to receive your portion of recovery.\n\nQ: What does it cost me to participate? A: Nothing. Securities class actions\nare handled on a pure contingency basis. No upfront fees, no retainer, no\nout-of-pocket costs.\n\nQ: What if I missed the lead plaintiff deadline? A: The deadline applies only\nto investors seeking lead plaintiff appointment. Class members who miss it can\nstill participate in any settlement or recovery.\n\nCONTACT:\nSueWallSt\nJoseph E. Levi, Esq.\nEd Korsinsky, Esq.\n33 Whitehall Street, 27th Floor\nNew York, NY 10004\njlevi@SueWallSt.com (mailto:jlevi@SueWallSt.com)\nTel: (888) SueWallSt\nFax: (212) 363-7171\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/gral-shareholder-alert-grail-inc-securities-class-action-lawsuit---investors-should-contact-suewallst-302803674.html\n(https://www.prnewswire.com/news-releases/gral-shareholder-alert-grail-inc-securities-class-action-lawsuit---investors-should-contact-suewallst-302803674.html)\n\nSOURCE SueWallSt.com\n\n\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1812443/suewallst-logo-1_Logo.jpg?id=OA2723114\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPn8Flbwla","title":"GRAL Shareholder Alert: Grail, Inc. Securities Class Action Lawsuit - Investors Should Contact SueWallSt","author":"PR Newswire","ticker":"GRAL","created":"2026-06-18T14:07:00.442Z","tickers":["GRAL"],"exchange":"NASDAQ","article_body":"GRAL Shareholder Alert: Grail, Inc. Securities Class Action Lawsuit - Investors Should Contact SueWallSt\n\nPR Newswire\n\nNEW YORK, June 18, 2026\n\nGrail Projected That the NHS-Galleri Trial Was Powered to Deliver a\nStatistically Significant Reduction in Late-Stage Cancers; Instead, the\nPrimary Endpoint Was Not Observed, and Investors Lost $51.32 Per Share\n\nNEW YORK, June 18, 2026 /PRNewswire/ -- Grail, Inc. (NASDAQ: GRAL) told\ninvestors its over 140,000-participant NHS-Galleri trial was designed to\nachieve a statistically significant reduction in Stage III and IV cancers. On\nFebruary 19, 2026, the company disclosed the opposite: the primary endpoint\n\"was not observed.\" GRAL shares collapsed 50.55% in a single day. Find out if\nyou can recover your investment losses\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4714095-11&h=2228923913&u=https%3A%2F%2Fsuewallst.com%2Flawsuits%2Fgrail-inc-class-action-lawsuit-gral%3Fprid%3D187605%26wire%3D4&a=Find+out+if+you+can+recover+your+investment+losses)\n or contact Joseph E. Levi, Esq. at jlevi@SueWallSt.com\n(mailto:jlevi@SueWallSt.com)  or (888) SueWallSt.\n\nFrom a closing price of $101.53 on February 19, 2026, shares fell to $50.21 on\nFebruary 20, 2026, a loss of $51.32 per share. The lead plaintiff deadline is\nAugust 4, 2026.\n\nThe Promise\n\nThroughout the Class Period of May 13, 2025 through February 19, 2026, Grail's\nleadership made specific, quantifiable representations about the NHS-Galleri\ntrial's trajectory:\n\n * On May 13, 2025, the company announced \"Positive Top-Line Results\" from the\nprevalent screening round, reporting a PPV \"substantially higher\" than the\n43% observed in PATHFINDER\n * Management stated the test was \"working in the real world,\" detecting\n\"clinically meaningful cancers and early-stage cancers in asymptomatic\nadults\"\n * On August 12, 2025, Grail's Chief Scientific Officer confirmed the study's\nsize \"was set to be able to deliver a statistically significant result\" on the\nprimary endpoint of late-stage cancer reduction\n * During the August 12, 2025 earnings call, executives promoted the NHS-Galleri\nreadout as a \"great calling card\" for global expansion and described the\nupcoming clinical utility data as a key catalyst\n * On October 20, 2025, management stated that PATHFINDER 2 results gave them \"a\nlot of confidence in the performance\" heading into the NHS-Galleri readout\nThe Reality\n\nOn February 19, 2026, Grail disclosed that the \"primary endpoint of\nstatistically significant Stage III-IV reduction was not observed.\" The\ncompany attributed this failure, in part, to \"probably need[ing] a longer\nfollow-up time to be able to [compare the study arms] adequately.\"\n\nThe lawsuit contends this admission reveals the three-year trial design and\nscreening duration were insufficient to demonstrate whether the primary\nendpoint was achievable, a limitation that should have been disclosed to\ninvestors rather than concealed behind repeated assurances of confidence.\n\nThe Numbers: Promised vs. Actual\n What Was Communicated                                                      What Actually Happened\n PPV \"substantially higher\" than 43%                                        Detailed results withheld from investors throughout Class Period\n Trial \"powered\" to deliver statistically significant late-stage reduction  Primary endpoint of Stage III-IV reduction not observed\n Three-year design sufficient for clinical utility                          Company admitted longer follow-up time was \"probably\" needed\n NHS-Galleri as a \"calling card\" for global expansion                       NHS and global partners left without the anticipated positive data\n PATHFINDER 2 gave \"a lot of confidence\" in performance                     Confidence did not translate to the primary endpoint\n\nWhat the Lawsuit Alleges About the Gap\n\nThe action claims that Grail's executives possessed information from their\ninternal review of first-round screening results that should have tempered\ntheir public confidence. By withholding detailed data under the stated\nrationale of protecting \"integrity\" of the trial, the complaint asserts\ndefendants potentially concealed known trendlines suggesting either a longer\ntimeline was necessary or that the probability of achieving the statistical\nreduction had diminished.\n\n\"Companies that make specific promises to investors about future performance\nhave an obligation to disclose known risks to those projections. When the gap\nbetween promise and reality is this significant, shareholders deserve to\nunderstand what was known and when.\" -- Joseph E. Levi, Esq.\n\nCheck whether you qualify to recover losses in the GRAL securities action\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4714095-11&h=1429650070&u=https%3A%2F%2Fsuewallst.com%2Flawsuits%2Fgrail-inc-class-action-lawsuit-gral%3Fprid%3D187605%26wire%3D4&a=Check+whether+you+qualify+to+recover+losses+in+the+GRAL+securities+action)\n or call (888) SueWallSt.\n\nABOUT SUEWALLST -- SueWallSt is a nationally recognized shareholder rights\nfirm. Over the past 20 years, the firm has secured hundreds of millions of\ndollars for aggrieved shareholders. Ranked in ISS Top 50 for seven consecutive\nyears.\n\nFrequently Asked Questions About the GRAL Lawsuit\n\nQ: What specific misstatements does the GRAL lawsuit allege? A: The complaint\nalleges Grail made materially false or misleading statements regarding the\nlikelihood of the NHS-Galleri trial achieving its primary endpoint of a\nstatistically significant reduction in Stage III and IV cancers. When the\ntrial's failure was disclosed on February 19, 2026, the stock price declined\nsharply.\n\nQ: How much did GRAL stock drop? A: Shares fell approximately 50.55%, a\ndecline of $51.32 per share, after the company disclosed that the primary\nendpoint of statistically significant Stage III-IV reduction was not observed.\nInvestors who purchased shares during the Class Period at artificially\ninflated prices may be entitled to compensation.\n\nQ: What do GRAL investors need to do right now? A: Gather brokerage records\nincluding purchase dates, share quantities, and prices paid. Contact SueWallSt\nfor a free, no-obligation evaluation at jlevi@SueWallSt.com\n(mailto:jlevi@SueWallSt.com)  or (888) SueWallSt. No immediate action is\nrequired to remain eligible as a class member.\n\nQ: What if I already sold my GRAL shares -- can I still recover losses? A:\nYes. Eligibility is based on when you purchased, not whether you still hold\nthem. Investors who bought during the Class Period and sold at a loss may\nstill participate.\n\nQ: Do I need to go to court or give testimony? A: No. The overwhelming\nmajority of class members never appear in court or give depositions. You\nsubmit a claim form to receive your portion of recovery.\n\nQ: What does it cost me to participate? A: Nothing. Securities class actions\nare handled on a pure contingency basis. No upfront fees, no retainer, no\nout-of-pocket costs.\n\nQ: What if I missed the lead plaintiff deadline? A: The deadline applies only\nto investors seeking lead plaintiff appointment. Class members who miss it can\nstill participate in any settlement or recovery.\n\nCONTACT:\nSueWallSt\nJoseph E. Levi, Esq.\nEd Korsinsky, Esq.\n33 Whitehall Street, 27th Floor\nNew York, NY 10004\njlevi@SueWallSt.com (mailto:jlevi@SueWallSt.com)\nTel: (888) SueWallSt\nFax: (212) 363-7171\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/gral-shareholder-alert-grail-inc-securities-class-action-lawsuit---investors-should-contact-suewallst-302803674.html\n(https://www.prnewswire.com/news-releases/gral-shareholder-alert-grail-inc-securities-class-action-lawsuit---investors-should-contact-suewallst-302803674.html)\n\nSOURCE SueWallSt.com\n\n\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1812443/suewallst-logo-1_Logo.jpg?id=OA2723114\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-06-18T14:07:00.476566215Z","server_sent_at_ms":1781791620476},"received_at":"2026-06-18T14:07:00.535Z","source_url":"https://www.prnewswire.com/news-releases/gral-shareholder-alert-grail-inc-securities-class-action-lawsuit---investors-should-contact-suewallst-302803674.html"},"analysis":{"id":"57259","press_release_id":"67843","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"legal_litigation","narrative":"SueWallSt issued a shareholder alert soliciting investors in Grail, Inc. (GRAL) to contact the firm regarding a securities class action lawsuit.\n\nThe release cites the February 19, 2026 disclosure that the NHS-Galleri trial failed to meet its primary endpoint, which caused shares to drop 50.55% to $50.21.\n\nThe lead plaintiff deadline is August 4, 2026. The release emphasizes that investors can recover losses at no cost or obligation.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Plaintiff-firm solicitation -- suppress."},"keyFigures":{"customDimensions":{"pre_drop_price":101.53,"post_drop_price":50.21,"share_loss_per_share":51.32,"share_price_drop_pct":"50.55%"}},"quotedText":"Companies that make specific promises to investors about future performance have an obligation to disclose known risks to those projections.","namedEntities":{"people":[{"name":"Joseph E. Levi","role":"Attorney at SueWallSt"},{"name":"Ed Korsinsky","role":"Attorney at SueWallSt"}],"products":["NHS-Galleri","Galleri"],"companies":[{"name":"Grail, Inc.","ticker":"GRAL","relationship":"defendant"},{"name":"SueWallSt","relationship":"plaintiff law firm"}],"dollarAmounts":[{"amount":"$51.32","context":"per-share loss after trial failure disclosure"},{"amount":"$101.53","context":"closing price on Feb 19, 2026"},{"amount":"$50.21","context":"closing price on Feb 20, 2026"}]},"materialImpact":{"score":1,"reasoning":"This is a plaintiff law-firm solicitation issued by SueWallSt (Levi & Korsinsky). It contains standard solicitation language ('contact SueWallSt', 'no cost or obligation', 'lead plaintiff deadline') and no new disclosure from the issuer. Per guardrails, this is low-impact noise."},"tickerRelevance":{"others":[],"primary":"GRAL"},"globalImportance":15,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"context":"GRAL is a known biotech name, but the event is purely legal marketing noise with no new fundamental data.","tickerTier":"mid-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"SueWallSt issued a shareholder alert soliciting investors in Grail, Inc. (GRAL) to contact the firm regarding a securities class action lawsuit.\n\nThe release cites the February 19, 2026 disclosure that the NHS-Galleri trial failed to meet its primary endpoint, which caused shares to drop 50.55% to $50.21.\n\nThe lead plaintiff deadline is August 4, 2026. The release emphasizes that investors can recover losses at no cost or obligation.","key_figures":{"customDimensions":{"pre_drop_price":101.53,"post_drop_price":50.21,"share_loss_per_share":51.32,"share_price_drop_pct":"50.55%"}},"named_entities":{"people":[{"name":"Joseph E. Levi","role":"Attorney at SueWallSt"},{"name":"Ed Korsinsky","role":"Attorney at SueWallSt"}],"products":["NHS-Galleri","Galleri"],"companies":[{"name":"Grail, Inc.","ticker":"GRAL","relationship":"defendant"},{"name":"SueWallSt","relationship":"plaintiff law firm"}],"dollarAmounts":[{"amount":"$51.32","context":"per-share loss after trial failure disclosure"},{"amount":"$101.53","context":"closing price on Feb 19, 2026"},{"amount":"$50.21","context":"closing price on Feb 20, 2026"}]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-06-18T14:07:21.546Z","global_importance":15,"audience_relevance":10,"importance_components":{"context":"GRAL is a known biotech name, but the event is purely legal marketing noise with no new fundamental data.","tickerTier":"mid-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"durationMs":20996,"modelName":"george-droid-qwen-72b"}}